Skip to main content

Advertisement

SpringerLink
Log in

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Purpose

Paclitaxel is an effective therapy for patients with solid tumors. While the albumin-bound formulation eliminates the hypersensitivity reaction caused by the Cremaphor solvent, significant peripheral neuropathy persists when given over the standard 30-min infusion time. We sought to determine if the incidence and severity of peripheral neuropathy could be reduced when the infusion time is lengthened to 2-h.

Methods

This was an open-label, single-arm, phase 2 study of albumin-bound paclitaxel given over 2 h. Twenty-five patients with advanced non-small-cell lung cancer were enrolled to determine whether the longer infusion reduced the severity of neuropathy compared to data from an earlier cohort of 40 similar patients treated over 30 min Patients received 125 mg/m2 of albumin-bound paclitaxel IV over 2 h without premedication on days 1, 8, and 15 of a 28-day cycle. Radiologic assessment was performed every 8 weeks.

Results

There was a significant 0.45 grade decrease in average peripheral neuropathy experienced by patients in the 2-h group versus the 30-min group (90% CI, 0.03-0.87). There was, in addition, a significant decrease in grade ≥2 peripheral neuropathy in patients treated over 2 h versus 30 min (28% vs. 55%, 2-sided P = 0.04). A decrease in grade ≥2 neutropenia (20% vs. 48%, 2-sided P = 0.07) was also observed. The median survival, 11 months, was the same for both groups.

Conclusion

Increasing the infusion time of albumin-bound paclitaxel from 30 min to 2 h resulted in a significant reduction in both average and grade ≥2 peripheral neuropathy without affecting survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Blum JL, Savin MA, Edelman G, Pippen JE, Robert N, Sandbach J, Carrasco S, O’Shaughnessy JA (2004) Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. J Clin Oncol (Meeting Abstracts) 22(14S):abstr 543

    Google Scholar 

  2. Eisenhauer E, ten Bokkel Huinink W, Swenerton K, Gianni L, Myles J, van der Burg M, Kerr I, Vermorken J, Buser K, Colombo N (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654–2666

    PubMed  CAS  Google Scholar 

  3. Freilich R, Balmaceda C, Seidman A (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology 47:115–118

    PubMed  CAS  Google Scholar 

  4. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803

    Article  PubMed  CAS  Google Scholar 

  5. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Hawkins MJ (2006) Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17:1263–1268

    Article  PubMed  CAS  Google Scholar 

  6. Ibrahim N, Samuels B, Page R, Guthrie G, Hortobagyi G (2002) Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): Efficacy and evidence of dose-dependent activity in two multicenter phase II studies.In: Proceedings of American Society Clinical Oncology 21:abstr 209

  7. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23:6019–6026

    Article  PubMed  CAS  Google Scholar 

  8. Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633–1642

    Article  PubMed  CAS  Google Scholar 

  9. Mielke S, Sparreboom A, Steinberg SM, Gelderblom H, Unger C, Behringer D, Mross K (2005) Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11:4843–4850

    Article  PubMed  CAS  Google Scholar 

  10. O’Shaughnessy J BJ, Sandbach J (2004) Weekly nanoparticle albumin paclitaxel (Abraxane) results in long-term disease control in patients with taxane-refractory metastatic breast cancer. In: Proceedings of 27th annual San Antonio breast cancer symposium, San Antonio, TX. abstr 1070

  11. Peretz T, Sulkes A, Chollet P, Gelmon K, Paridaens R, Gorbonuva V, Catimel G, Kuhnle H, WtB Huinink, Khayat D, Ditrich C, Klaassen U, Bergh J, Wilking N, Nabholtz JM, Calabresi F, Tubiana-Hulin M, Chazard M, Gallant G, Diergarten K, Westberg R, Bogaert J, Renard J, Weil C (1995) A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur J Cancer 31:75–75

    Article  Google Scholar 

  12. Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:1074–1080

    Article  PubMed  CAS  Google Scholar 

  13. Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ, Kris MG (2008) Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 26:639–643

    Article  PubMed  CAS  Google Scholar 

  14. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, Parisi A, Pham Tran N, Olivares R, Berille J (2000) A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small-cell lung cancer (NSCLC). Lung Cancer 27:145–157

    Article  PubMed  CAS  Google Scholar 

  15. Roytta M, Raine S (1986) Taxol induced neuropathy: chronic effects of local injection. J Neurocytol 15:483–496

    Article  PubMed  CAS  Google Scholar 

  16. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all her-2 overexpressors and random assignment to trastuzumab or not in her-2 non-overexpressors: final results of cancer and leukemia group b protocol 9840. J Clin Oncol 26:1642–1649

    Article  PubMed  CAS  Google Scholar 

  17. Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, Shibata HR, Baez L, DeFusco PA, Davila E, Tipping SJ, Bearden JD, Thirlwell MP (1999) Randomized trial of 3 h versus 24-h infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: national surgical adjuvant breast and bowel project protocol b-26. J Clin Oncol 17:3403–3411

    PubMed  CAS  Google Scholar 

  18. Socinski M, Bondarenko I, Karaseva N, Makhson A, Vynnychenko I, Okamoto I, Hon J (2010) Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with Cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 28:abstr 7511

    Google Scholar 

  19. Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV, Yablonsky PK, Bhar PH, Iglesias J (2010) A dose finding study of weekly and every 3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol 5:852–861

    Article  PubMed  Google Scholar 

  20. Stokes M, Davis C, Koch G (2000) Categorical data analysis using the sas system, 2nd edn. SAS Institute and Wiley, Cary

    Google Scholar 

Download references

Acknowledgments

Grant support is given by Abraxis BioScience, Los Angeles, CA.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, H1011, New York, NY, 10065, USA

    Paul K. Paik, Leonard P. James, Gregory J. Riely, Christopher G. Azzoli, Vincent A. Miller, Kenneth K. Ng, Mark G. Kris, Erin Moore & Naiyer A. Rizvi

  2. Department of Biostatistics, Memorial Sloan–Kettering Cancer Center, New York, NY, 10065, USA

    Camelia S. Sima

  3. Department of Radiology, Memorial Sloan–Kettering Cancer Center, New York, NY, 10065, USA

    Robert T. Heelan & Naiyer A. Rizvi

Authors
  1. Paul K. Paik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonard P. James
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory J. Riely
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher G. Azzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincent A. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenneth K. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Camelia S. Sima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert T. Heelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mark G. Kris
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Erin Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Naiyer A. Rizvi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naiyer A. Rizvi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paik, P.K., James, L.P., Riely, G.J. et al. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion. Cancer Chemother Pharmacol 68, 1331–1337 (2011). https://doi.org/10.1007/s00280-011-1621-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1621-0

Keywords

Search

Navigation